Mehmet Kizilkaya | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Mehmet Kizilkaya
Researcher Mehmet Kizilkaya
Affiliation Trabzon Kanuni Training and Research Hospital
Country Turkey
Google Scholar ID LoT5L1kAAAAJ
Documents 1
Citations 1
h-index 0
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-0266-3919

Mehmet Kizilkaya

Trabzon Kanuni Training and Research Hospital, Turkey

Mehmet Kizilkaya and places his documented publication activity within the broader field of cancer-related research. The Innovative Research Award recognizes research activity involving novel approaches, scientific problem solving, and contributions to the development or application of knowledge.[1][2]

Abstract

Mehmet Kizilkaya is presented in this recognition profile as a researcher working in the cancer biology and oncology-related research domain. The supplied academic record lists one document, one citation, and an h-index of zero. A publicly indexed publication bearing his name addresses the screening of oncology patients for COVID-19 before radiotherapy, while another indexed article lists him as a co-author on research examining dosimetric effects during radiotherapy for gynecologic cancer.[1][2]

Keywords

Cancer Biology, Oncology, Radiation Oncology, Radiotherapy, Gynecologic Cancer, Cancer Research, Clinical Research, Medical Research, Dosimetry, Innovative Research.

Introduction

Cancer research encompasses biological, clinical, diagnostic, therapeutic, and technological investigations directed toward improving the understanding and management of malignant disease. Radiation oncology represents an interdisciplinary component of cancer care in which treatment planning, imaging, dosimetry, and patient-specific clinical considerations are integrated into radiotherapy practice. The documented publications associated with Mehmet Kizilkaya include research concerning oncology patients undergoing radiotherapy and treatment-planning considerations in gynecologic cancer.[1][2]

Research Profile

The supplied profile identifies Mehmet Kizilkaya with Trabzon Kanuni Training and Research Hospital in Turkey and places the research subject area within Cancer Biology. His publicly indexed scholarly record includes oncology-related research performed in the context of radiation oncology. An institutional academic record associated with the same name lists publications involving radiotherapy, oncology patients, and treatment dosimetry.[1][2]

  • Research area supplied for this recognition profile: Cancer Biology.
  • Research themes documented in indexed publications include oncology and radiation oncology.
  • Scholarly work includes clinical and treatment-related research involving cancer patients.
  • Google Scholar profile identifier: LoT5L1kAAAAJ.

Research Contributions

One documented contribution is the 2022 publication Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. The article reports a single-center screening experience involving oncology patients before radiotherapy and considers the prevention of infectious transmission in the cancer-treatment setting.[1]

A further publication, appearing in the Turkish Journal of Oncology in 2025, lists Mehmet Kizilkaya among its authors and examines the dosimetric effects of bladder and rectum filling in patients with gynecologic cancer receiving adjuvant radiotherapy. The study was published with DOI 10.5505/tjo.2024.4429.[2]

Publications

  • Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. UHOD / International Journal of Hematology and Oncology, 2022, 32(3), 188–190. DOI: 10.4999/uhod.226389.[1]
  • Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 2025, 40(1), 11–19. DOI: 10.5505/tjo.2024.4429.[2]

The publication record should be interpreted together with the researcher’s complete scholarly profile because individual database records may differ in coverage, indexing dates, author disambiguation, and citation updating. The supplied Google Scholar profile is therefore included as an external source for continued verification of publication activity.[3]

Research Impact

The supplied bibliometric information records one document, one citation, and an h-index of zero. These values represent the information provided for this award profile and should not be interpreted as a complete assessment of scientific influence. Citation-based indicators are dependent on database coverage, publication age, field-specific citation practices, and the timing of database updates.[3]

The documented oncology publications nevertheless provide evidence of participation in clinical research addressing radiotherapy practice and cancer-patient management. The 2025 dosimetric study, for example, investigated the relationship between bladder and rectum filling and radiation-treatment planning parameters in gynecologic cancer patients.[2]

Award Suitability

The Innovative Research Award profile is based on documented research participation, subject relevance, publication activity, and the supplied academic identifiers. Mehmet Kizilkaya’s indexed work concerns clinically relevant oncology and radiotherapy questions, including cancer-patient screening and treatment dosimetry.[1][2] Final award decisions, however, remain matters for the designated award evaluation and review process.

Conclusion

Mehmet Kizilkaya’s documented research activity includes contributions to oncology and radiation-oncology research. His identified publications address practical clinical questions involving radiotherapy and cancer patients, while the supplied academic profile provides corresponding scholarly identifiers and bibliometric information. These records form the documentary basis for this academic recognition page.[1][2][3]

References

  1. Kizilkaya, M., Genc, M., Aksu, M. G., Koca, T., & Korcum, A. F. (2022). Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. International Journal of Hematology and Oncology, 32(3), 188–190.
    https://doi.org/10.4999/uhod.226389
  2. Koca, T., Aksoy, R. A., Atak, E., Kizilkaya, M., Bilek, Y., Tunçel, N., Sarpün, İ. H., & Korcum, A. F. (2025). Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 40(1), 11–19.
    https://doi.org/10.5505/tjo.2024.4429
  3. Google Scholar. (n.d.). Mehmet Kizilkaya — Google Scholar profile. Google Scholar.
    https://scholar.google.com/citations?user=LoT5L1kAAAAJ&hl=tr
  4. ORCID. (n.d.). Mehmet Kizilkaya — ORCID record. ORCID.
    https://orcid.org/0000-0003-0266-3919
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Hany Ahmed | Cancer Biology | Best Scholar Award

Published on by Molecular Biologist

 

Best Scholar Award

Hany Ahmed
Al Azhar University , Egypt

Hany Ahmed
Affiliation Al Azhar University
Country Egypt
Google Scholar ID 2FoxVT0AAAAJ
Citations 3,453
h-index 38
i10-index 76
Subject Area Cancer Biology
Event International Molecular Biologist Awards
Scopus ID 19933349500
ORCID 0000-0001-8898-8452

Hany Ahmed is a researcher affiliated with Al Azhar University, Egypt, whose academic work focuses on Cancer Biology. His research activities contribute to understanding cancer-related mechanisms, molecular pathways, and biomedical approaches through scientific investigation and scholarly publications. [1]

Abstract

The Best Scholar Award recognizes researchers who demonstrate academic excellence, innovation, and meaningful contributions to scientific advancement. Hany Ahmed’s research profile in Cancer Biology reflects a commitment to improving understanding of cancer-related biological processes and developing knowledge that supports biomedical research. [2]

Keywords

  • Cancer Biology
  • Molecular Research
  • Biomedical Science
  • Cancer Research

Introduction

Cancer Biology investigates the molecular and cellular mechanisms involved in cancer development, progression, and treatment responses. Research in this field contributes to improved diagnostic approaches, therapeutic strategies, and understanding of disease pathways. Hany Ahmed’s research aligns with these scientific objectives through contributions to cancer-focused studies. [3]

Research Profile

Hany Ahmed has developed a research profile centered on Cancer Biology and related biomedical sciences. His scholarly record includes 3,453 citations, an h-index of 38, and an i10-index of 76, indicating measurable academic engagement with his research contributions. [1]

Research Contributions

  • Investigation of cancer-related molecular mechanisms.
  • Contribution to biomedical and biological research studies.
  • Advancement of scientific knowledge through academic publications.

Publications

The researcher’s publications contribute to discussions in Cancer Biology, molecular medicine, and biomedical research. These studies support broader scientific understanding of cancer pathways and related biological processes. [4]

Research Impact

Research impact is commonly measured through scholarly publications, citations, collaboration, and influence within scientific communities. Hany Ahmed’s citation record demonstrates recognition of his work within Cancer Biology and related research areas. [2]

Award Suitability

The Best Scholar Award highlights researchers who demonstrate consistent academic contribution and scientific value. Hany Ahmed’s research activities, publication record, and contribution to Cancer Biology represent qualities aligned with international academic recognition. [5]

Conclusion

Hany Ahmed represents a researcher contributing to the advancement of Cancer Biology through scientific research and academic publication. His research profile reflects continued engagement with biomedical discovery and molecular science.

References

  1. Elsevier. (n.d.). Scopus author details: Hany Ahmed, Author ID 19933349500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=19933349500
  2. ORCID. (n.d.). Hany Ahmed ORCID Researcher Profile.
    https://orcid.org/0000-0001-8898-8452
  3. Google Scholar. (n.d.). Hany Ahmed Scholar Citation Profile.
    https://scholar.google.com/citations?user=2FoxVT0AAAAJ&hl=a
  4. Hany Ahmed. (2025). synthesis and biological evaluation: New Dimensions. wiley.
    https://doi.org/10.1158/2159-8290.CD-21-1059
  5. International Molecular Biologist Awards. (n.d.). Award Information Portal.
    https://molecularbiologist.org/

 

Rongbin Li | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Rongbin Li | Cancer Biology | Best Researcher Award 

Doctorate, at Peking University, China.

Dr. Rongbin Li is a dynamic and emerging immunologist affiliated with the Department of Immunology, School of Basic Medical Sciences, and NHC Key Laboratory of Medical Immunology, Peking University, Beijing, China. He also contributes significantly to the Peking University Center for Human Disease Genomics. With a robust academic background in clinical and immunological sciences, Dr. Li’s research is focused on colitis-associated carcinogenesis and the molecular pathways that contribute to inflammatory bowel disease (IBD) and colorectal cancer. His recent milestone includes a first-author publication in the high-impact journal Cellular and Molecular Gastroenterology and Hepatology, coupled with a patent application for CMTM3 as a therapeutic target. Dr. Li has also presented his research at national congresses, underlining his capability in both lab innovation and scientific communication. His dedication to unraveling immune mechanisms promises meaningful breakthroughs in medical immunotherapy. 🌟

Professional Profile

ORCID

🎓 Education

Dr. Rongbin Li pursued his Ph.D. in Immunology at the prestigious Peking University from 2019 to 2024, focusing on medical immunology and disease genomics. His academic journey was marked by exceptional research, culminating in a first-author publication and a nationally recognized patent. Prior to this, he earned a B.Med. in Clinical Medicine from Hebei University of Engineering (2014–2019), where he was trained in clinical diagnostics, pathophysiology, and foundational immunology. His educational progression reflects a strong foundation in both theoretical knowledge and experimental methodologies. Through rigorous coursework, extensive lab work, and early exposure to clinical sciences, Dr. Li has built a dual competence in clinical medicine and molecular immunology, making him uniquely positioned to bridge the gap between bedside and bench. His multidisciplinary academic background underpins his innovative contributions to immunotherapy and cancer research. 🎓🧪

💼 Experience 

Dr. Li’s professional experience is deeply intertwined with cutting-edge immunological research at Peking University. During his doctoral tenure, he was entrusted with a National Natural Science Foundation of China (NSFC) funded project where he led experimental design, data analysis, and manuscript preparation. In collaboration with Peking University Third Hospital, he played a pivotal role in uncovering the mechanism of CMTM3 in aggravating colitis and promoting carcinogenesis, leading to a patent application. His responsibilities included conceptualization, methodology design, formal analysis, and software development, demonstrating expertise in both wet lab and computational environments. He also delivered an oral presentation at the 15th National Congress of Immunology (2023), showcasing his communication skills and subject mastery. His current research on therapeutic targets for IBD reflects a strong commitment to translational medicine. With a blend of lab skills, analytical capabilities, and cross-institutional teamwork, Dr. Li exemplifies the modern biomedical researcher. 🔬👨‍🔬

🔍 Research Interest 

Dr. Rongbin Li’s core research interest revolves around colitis-associated carcinogenesis, with a focus on the immunological and molecular interactions that promote inflammatory bowel disease (IBD) and colorectal cancer. 🧫 His primary interest lies in deciphering the role of CMTM3, a novel therapeutic target that stabilizes CLTC and disrupts VE-cadherin regulation via clathrin-mediated pathways. His ongoing work investigates how immune and endothelial interactions exacerbate inflammatory responses and facilitate tumorigenesis. He also explores the mechanistic crosstalk between inflammation and epithelial-mesenchymal transition (EMT), with the broader goal of developing CMTM3-targeted biologics or small molecules. His interdisciplinary approach combines molecular immunology, cancer biology, and vascular biology, aimed at discovering actionable targets for precision medicine. By merging bioinformatics, cellular assays, and in vivo models, Dr. Li aspires to translate fundamental immunological discoveries into clinically viable therapies, particularly for patients suffering from chronic inflammation-related cancers. 🌐🧠

🏆 Awards 

Dr. Rongbin Li’s promising contributions to immunology have garnered notable recognition. His recent work funded by the National Natural Science Foundation of China (NSFC) signifies his capability to lead and innovate in high-stakes research environments. 🧪 His first-author article in Cellular and Molecular Gastroenterology and Hepatology stands as a testament to his scholarly excellence, originality, and scientific rigor. In 2023, he was selected for an oral presentation at the 15th National Congress of Immunology, one of the most prestigious scientific forums in China. Additionally, his innovative findings led to a patent application titled “CMTM3 as a therapeutic target for IBD and colorectal cancer” (Appl. No: 2025104021503), demonstrating real-world impact and translational potential. These achievements position him as a strong candidate for the Best Researcher Award, celebrating his impactful early-career journey, commitment to scientific advancement, and potential for future breakthroughs in immunology and cancer therapy. 🏅

📚 Top Noted Publications 

Dr. Rongbin Li’s scholarly work has made a significant impact in the field of immunology. His first-author research article, published in the reputable journal Cellular and Molecular Gastroenterology and Hepatology (2025), elucidates the critical role of CMTM3 in colitis-associated carcinogenesis. The study reveals how CMTM3 stabilizes CLTC and contributes to vascular endothelial dysfunction, advancing our understanding of inflammation-driven cancer mechanisms.

Key Findings

This research identifies CMTM3 (CKLF-like MARVEL transmembrane domain-containing 3) as a significant contributor to colitis-associated colorectal cancer (CAC). The study elucidates that CMTM3 stabilizes CLTC (clathrin heavy chain), enhancing clathrin-mediated endocytosis. This process leads to the internalization and degradation of VE-Cadherin, a crucial adhesion molecule in vascular endothelial cells. The loss of VE-Cadherin disrupts endothelial integrity, increasing vascular permeability, which exacerbates colitis and fosters a pro-inflammatory environment conducive to carcinogenesis.​BioMed Central

Citation Information

As of the latest database update, this article has been cited by two other publications, indicating its emerging influence in the field of gastrointestinal oncology.​

Related Research

Previous studies have explored the role of CMTM3 in various cancers. For instance, research has shown that CMTM3 can mediate angiogenesis by regulating the cell surface availability of VE-Cadherin in endothelial adherens junctions . These findings align with the current study’s observations on CMTM3’s impact on endothelial function and its potential role in cancer progression.

Conclusion

Dr. Rongbin Li shows exceptional promise as a medical immunologist with impactful research on colitis-associated cancer, underpinned by innovation (a therapeutic patent), prestigious institutional affiliation, and peer-reviewed publication. While citation metrics and broader scholarly visibility are still developing, the quality, novelty, and translational potential of his work make him well-suited for the Best Researcher Award.

Liu Yang | oncology | Best Researcher Award

Published on by Molecular Biologist

Prof Dr. Liu Yang | oncology | Best Researcher Award 

professor, The Affiliated Cancer Hospital of Nanjing Medical University, China.

Yang Liu is a Chief Physician and Associate Professor specializing in colorectal surgery. With expertise in minimally invasive and robotic surgeries, he performs over 150 advanced procedures annually. His contributions to medical research and patient care make him a key figure in the field of colorectal cancer treatment.

Profile

Scopus

Education

Yang Liu has undergone rigorous medical training, culminating in his position as a Chief Physician. He is an accomplished researcher and associate professor, continuously contributing to the development of colorectal cancer treatments.

Experience

Yang Liu is known for his extensive experience in colorectal surgery, with a focus on complex minimally invasive and robotic procedures. His surgical expertise, combined with his research on cancer genomics, has solidified his reputation in both clinical practice and academic settings.

Research Interests

Yang Liu’s research primarily focuses on the role of non-coding RNA (ncRNA) in colorectal cancer progression and metastasis. He is involved in various projects exploring epigenetic mechanisms and targeted therapies for colorectal cancer. His goal is to advance the understanding and treatment of this complex disease.

Awards

  • 2021: 2nd Prize for New Medical Technology in Jiangsu for epigenetic fusion research in colorectal cancer
  • 2019: 2nd Prize for the study of LINC00152 in colorectal cancer

Publications

  1. Multi-Dimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
  2. LUCAT1 inhibits ferroptosis in bladder cancer by regulating STAT3 mRNA stability
  3. Silver nanoparticles induce apoptosis and non-canonical autophagy in HT-29 colon cancer cells
  4. Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer

Conclusion

Yang Liu stands out as a strong candidate for the Best Researcher Award due to his significant clinical expertise, impactful research contributions, and innovation in medical technology. His leadership in colorectal surgery and mentorship roles, combined with a growing portfolio of high-impact publications and patents, underscore his potential for making groundbreaking advances in cancer treatment. To further enhance his candidacy, he could focus on increasing his international presence and broadening his research scope. Nonetheless, his accomplishments to date make him a highly competitive candidate for the award.

 

Mahnoosh Mokhtarinejad | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Mrs . Mahnoosh Mokhtarinejad | Cancer Biology | Best Researcher Award 

Laboratory Expert , Faculty of Pharmacy and Pharmaceutical of sciences, Hormozgan University of Medical sciences, Iran .

Mahnoosh Mokhtarinejad is a researcher in genetics, with expertise in cancer biology, gene expression, and bioinformatics. Based in Iran, she holds advanced degrees in Human Genetics and Cellular and Molecular Biology. She currently works as a laboratory expert and technician at the Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Iran. Her research focuses on the molecular aspects of cancer, particularly head and neck squamous cell carcinoma (HNSCC).

Profile

Scopus

Education

🎓 Mahnoosh earned her Master’s degree in Human Genetics from Tehran University of Medical Science (2016-2018), where her thesis explored the expression of specific lncRNAs and mRNAs in HNSCC. Prior to this, she completed a Bachelor’s degree in Cellular and Molecular Biology-Genetics from Shahid Chamran University of Ahvaz (2011-2015), with coursework covering biochemistry, genetics, and oncology.

Experience

🧪 Mahnoosh has worked as a Laboratory Expert and Technician at Hormozgan University of Medical Sciences since 2021, where she conducts research on gene expression in cancer cells. She also serves as a teaching assistant, guiding pharmacy students through laboratory experiments. She previously worked as a Medical Sales Representative for Niksan Salamat Behbood Company in 2020.

Research Interests

🔬 Mahnoosh’s research interests revolve around cancer biology, gene expression regulation, epigenetics, pharmacogenetics, and bioinformatics. She is particularly focused on the molecular mechanisms underlying cancers like HNSCC, exploring the role of long non-coding RNAs (lncRNAs) and tumor suppressor genes.

Awards

🏆 Mahnoosh has been actively engaged in academic and professional circles, contributing to her field through participation in congresses such as the IRHRC Annual Meeting on Reproductive and Infertility Updates.

Publications

📚 2024
Mokhtarinejad, M., Pirhoushiaran, M., Heidarzadehpilehrood, R., Hesami, S., Azmoudeh-Ardalan, F., Shakoori Farahani, A. Upregulated long non-coding RNAs TMPO-AS1, DDX11-AS1, and POLE gene expression predict poor prognosis in head and neck squamous cell carcinoma (HNSCC). Gene Reports, cited by 6 articles.

📚 2020
Mehrabi, S., Pirhoushiaran, M., Eshaghkhani, Y., Teimourzadeh Baboli, A., Mahmoudi, A., Zarifian Yeganeh, R., Abdollahzadeh, R., Sadeghi Rad, H., Mokhtarinejad, M., Shakoori Farahani, A. Molecular Analysis of EGFR and PIK3CA Genetic Mutations in Iranian Patients with Head and Neck Squamous Cell Carcinoma. International Journal of Pharmaceutical and Phytopharmacological Research, cited by 12 articles.

📚 2023
Jamil, M., Mohammadi-Bardbori, A., Safa, O., Nikpoor, A.R., Bakhtari, A., Mokhtarinejad, M., Naybandi Zadeh, S., Shadboorestan, A., Omidi, M. Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis. Drug Research, cited by 4 articles.

Conclusion

Mahnoosh Mokhtarinejad is a strong candidate for the Best Researcher Award, with a rich background in cancer genetics, particularly focusing on molecular aspects of head and neck squamous cell carcinoma. Her publications in reputable journals, technical expertise, and role as a laboratory expert reflect her dedication to scientific advancement. However, expanding her leadership in large-scale research projects and enhancing her international exposure could further elevate her profile for this award. Overall, her work in cancer genetics holds significant promise and aligns well with the criteria for recognition in research excellence.